Duarte, Luisa F.Vázquez, YaneisiDiethelm-Varela, BenjamínPavez, ValentinaBerríos-Rojas, RoslyeMéndez, ConstanzaRiedel, Claudia A.White, Jessica A.Kalergis, Alexis M.Bueno, Susan M.González, Pablo A.2023-12-062023-12-062023-10-01Journal of Infectious Diseases, Volume 228, Issue 7, Pages 857 - 867, 1 October 202300221899https://repositorio.unab.cl/xmlui/handle/ria/54456INDEXACIÓN: SCOPUS.Background: We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection. Methods: Serum samples obtained from volunteers immunized with CoronaVac (2 and 3 doses), breakthrough case patients, and from convalescent individuals were analyzed to determine the immunoglobulin (Ig) G responses against 3 structural and 8 nonstructural SARS-CoV-2 antigens. Results: Immunization with CoronaVac induced higher levels of antibodies against the viral membrane (M) protein compared with convalescent subjects both after primary vaccination and after a booster dose. Individuals receiving a booster dose displayed equivalent levels of IgG antibodies against the nucleocapsid (N) protein, similar to convalescent subjects. Breakthrough case patients produced the highest antibody levels against the N and M proteins. Antibodies against nonstructural viral proteins were present in >50% of the convalescent subjects. Conclusions: Vaccinated individuals elicited a different humoral response compared to convalescent subjects. The analysis of particular SARS-CoV-2 antigens could be used as biomarkers for determining infection in subjects previously vaccinated with CoronaVac. © 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.enantibody responsesbreakthroughCoronaVacSARS-CoV-2vaccinationArtículoCC BY 4.0 DEED Attribution 4.0 International10.1093/infdis/jiad320